MétaCan
Menu
Back to cohort

Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.

2016· article· en· W2780350829 on OpenAlexaff
Anna Spreafico, Eric X. Chen, Solmaz Sahebjam, Daniel J. Renouf, Karen Kelly, A. Craig Lockhart, Ulka N. Vaishampayan, Sebastién J. Hotte, Albiruni R. Abdul Razak, Lisa Wang, Lee-Anne Stayner, Alanna Bougie, Helen X. Chen, S. Percy Ivy, Lillian L. Siu

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMelanoma and MAPK Pathways
Canadian institutionsJuravinski Cancer CentreBC Cancer AgencyPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineRashPharmacokineticsInternal medicineCancerMelanomaGastroenterologyRefractory (planetary science)CmaxToxicityCohortOncologyUrology

Abstract

fetched live from OpenAlex

2578 Background: Trametinib (T), an orally available MEK 1/2 inhibitor, is FDA approved for BRAFV600E/K mutant advanced melanoma, at the single agent RP2D of 2 mg QD. Its clinical development has involved a variety of refractory cancers. A phase I study was conducted to establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetic (PK) profile of T in advanced solid tumor patients (pts) with varying degrees of hepatic dysfunction (HD). Methods: Advanced cancer pts with ECOG ≤2, adequate renal and bone marrow functions, were stratified (NCI ODWG Criteria) into 4 HD groups: normal (NO), mild (ML), moderate (MD), severe (SV). T was given QD on a 28-days cycle, with dose escalation occurring in sequential cohorts of pts within each HD group (starting dose: NO, ML: 2mg; MD: 1.5 mg; SV: 1mg). PK samples were collected at days 15-16 in cycle 1. Results: Between Mar '14-Nov '15, 30 (17 NO, 7 ML, 3 MD, 3SV) pts were treated. Median age 60, male 43%, ECOG≤1: 97%. Common tumor types: GI non-CRC 17%, NSCLC 17%, uveal melanoma 13%. All cohorts drug-related AEs (All Grades/Grade 3-4): skin rash 73%/7%, increased transaminases 43%/7%, fatigue 40%/7%. No DLTs so far occurred in ML, MD and SV groups. Dose delay and dose reduction occurred in 47% and 20% of all pts respectively. PK data were available in 10 NO and 6 ML HD cohort pts (Table). Of 23 pts evaluable for response, 13 (56%) had stable disease and 2 (9%) pts partial response (NSCLC; ovarian). Median duration of response was 3.6 months (range 1-13.7+). Conclusions: The RP2D for trametinib in ML group, which has completed accrual, is 2 mg QD. The PK profile in NO and ML groups is comparable. Thus far, T appeared to be tolerated within all groups. Accrual in MD and SV groups is ongoing at 1.5 mg QD and 1 mg QD respectively. Clinical trial information: NCT02070549.PK analysis for NO and ML groups. NO: 2mg QD (n=10) 90% CI ML: 2 mg QD (n=6) 90% CI AUC (ng*hr/ml) (SD) 507.5 ± 189.0 (397.9 – 617.0) 387.7 ± 201.3 (222.2 – 553.3) Cmax (ng/ml) (SD) 30.37 ± 12.15 (23.3 – 37.4) 29.53 ± 15.88 (16.5 – 42.6) Cmin (ng/ml) (SD) 16.30 ± 6.47 (12.6 – 20.1) 12.14 ± 6.95 (6.4 – 17.9) CL/F (L/hr) 4.51 ± 1.85 (3.44 – 5.57) 6.20 ± 2.82 (3.88 – 8.52) Tmax (hr) (range) median: 2 (1-4) median: 1 (0-2)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.400
Teacher spread0.328 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicMelanoma and MAPK PathwaysFrench-language works237,207